Case Study: 63-Year-Old Man With Multiple Myeloma

News
Video

A team of multiple myeloma experts review a patient profile, offering preliminary insights and underscoring the importance of advanced practice providers in optimizing patient care.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Image of a woman with dark hair wearing a floral shirt in front of a blurred background
      Nurse Practitioners in Cancer Research: Recruitment, Protocols, and Documentation
      Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
      Monitoring Acute CRS Following T-cell Redirection Therapy for Myeloma
      Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
      Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
      Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma
      Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma
      Clinical Advice on Caring for Patients Treated With Talquetamab
      Clinical Advice on Caring for Patients Treated With Talquetamab
      Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM
      Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM
      Managing Toxicities From Talquetamab in Multiple Myeloma
      Managing Toxicities From Talquetamab in Multiple Myeloma
      Strategies for Discussing Potential Adverse Effects of Talquetamab in MM
      Strategies for Discussing Potential Adverse Effects of Talquetamab in MM
      Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab
      Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab
      Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma
      Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma
      Related Content
      Rendering of red blood cells with multiple myeloma

      Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM

      Roman Fabbricatore
      March 30th 2025
      Article

      Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.

      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

      Microscope image of multiple myeloma

      Older Patients with Lenalidomide-Refractory MM May Face Treatment Gaps

      Roman Fabbricatore
      March 10th 2025
      Article

      Real-world data show that older adults with lenalidomide-refractory MM have poor survival outcomes after 1 to 3 lines of therapy.

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

      Lindsay Fischer
      April 13th 2023
      Podcast

      Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

      Simple white line illustration of red blood cells on a yellow background

      Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

      Ashling Wahner
      January 30th 2025
      Article

      The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

      an illustration of a bone with circles around it indicating a microscope, test tubes and prescriptions

      Subcutaneous Isatuximab Non-Inferior to IV in Relapsed/Refractory Myeloma

      Caroline Seymour
      January 10th 2025
      Article

      In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd.